News Hub | News Direct

Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

A Leap in Ionization Prediction: ACD/Labs Unveils Groundbreaking Version of Modeling Software at ACS Fall 2023

ACD/Labs

Version 2023 of the Classic pK a calculator in Percepta® includes a significantly expanded training set for improved prediction accuracy, broader chemical applicability; and algorithmic changes that deliver impressive speed enhancements to this industry-leading software. 26 years after the release of their first ionization predictor, ACD/Labs, an informatics company that develops and commercializes software in support of R&D, today announces the release of their latest version of molecular property calculators on the Percepta Platform. Andrew Anderson, Vice President of Innovation and Informatics Strategy at ACD/Labs says, “Metaphorically speaking, data is the 'heartbeat' of chemistry R&D, generated during either physical experimentation or in silico calculation. In an age where research groups are looking to harness the power of data in artificial intelligence and machine learning frameworks, prediction reliability is one of the most important success determinants. Our new version of Percepta pK a exemplifies our commitment to enabling reliable, data-driven R&D. Many molecules under investigation in R&D labs are susceptible to ionization. Knowing 'when and where' is of paramount importance since the same chemical might behave differently under different conditions. Reliable and accurate predictions not only help computational scientists develop accurate SAR models; these predictions also help scientists account for the ionization properties of molecules during their 'design, make, test' cycles. Finally, accurate descriptor prediction will empower data scientists with reliable insights for the 'next crop' of ground-breaking innovation activity. We're proud to support our large user community with this important new release.” Ionization—frequently expressed as the acid dissociation constant for molecules with ionizable centers, or pK a —is a fundamental property that affects the behavior of chemical compounds in environmental, pharmaceutical, agrochemical, and other fields. It plays a crucial role in defining other properties like lipophilicity (log D ), aqueous solubility, toxicity (hERG), and helps with understanding the chemical reactivity of molecular entities. In biopharma, it is used to model more complex ADME behaviors such as absorption, bioavailability, and clearance, and to develop delivery systems and formulations for new drug entities. pK a values are used by researchers to understand and modulate the behavior of molecules in biological and environmental systems, and to successfully apply separation technology such as chromatography. Furthermore, predictive software is an integral part of green chemistry initiatives and sustainable practices, providing a reliable alternative to physical experiments. “This new release is a shining example of our continued commitment to excellence,” said Andrius Sazonovas, Head of Percepta Software Development at ACD/Labs. “Since the introduction of our first ionization predictor in 1997; my colleagues and I have overseen the improvements to our computational software and have worked on numerous customer projects to apply our modeling methodology to proprietary datasets at innovative chemistry-driven organizations. In our tests of Percepta version 2023, we saw a 5–10 fold increase in the speed of calculation of pK a for various datasets. Significant improvement was also observed for prediction accuracy. While this varies for different datasets, 120% improvement was noted for a set of ~370 novel pharmaceutical compounds with ~600 pK a values in a recent collaborative project. This release truly represents the next generation of pK a prediction from ACD/Labs, with respect to performance, reliability, and speed.” For more information about in silico predictions available from ACD/Labs, meet our team at Booth 933 in the ACS exhibition hall or visit acdlabs.com/percepta. ACD/Labs is a leading provider of scientific software for R&D. We help customers in >94 countries around the world assemble digitized analytical, structural, and molecular information for effective decision-making, problem solving, and product lifecycle control. Our enterprise technologies enable automation of molecular characterization and facilitate chemically intelligent knowledge management. ACD/Labs provides worldwide sales and support and brings decades of experience and success helping organizations innovate and create efficiencies in their workflows. For more information, please visit www.acdlabs.com. Follow us on Twitter and LinkedIn. Contact Details ACD/Labs Sanji Bhal +1 416-368-3435 media@acdlabs.com Racepoint Global Allison Matthews +1 617-624-3248 amatthews@racepointglobal.com Company Website https://www.acdlabs.com/

August 14, 2023 12:00 PM Eastern Daylight Time

Article thumbnail News Release

Kuros Biosciences "doing extremely well" in innovative spinal fusion treatments

Kuros Biosciences

Kuros Biosciences (SIX:KURN) CEO Joost de Bruijn speaks to Thomas Warner from Proactive about the innovative work the spinal fusion biologics-focused company has been focused on recently and looks ahead to what investors can expect from it in the future. Kuros Biosciences is headquartered in Switzerland with locations across the Netherlands and the USA, and specialises in autologous biologics aimed at regenerating bone tissue, with a specific focus on spinal fusions. Its flagship and first commercial product MagnetOs, is a unique synthetic bone graft that de Bruijn explains stands out for its unique surface topography that stimulates bone formation post-implantation, thereby setting it apart from other synthetic alternatives. De Bruijn also a product still in development called Fibrin PTH, a pharma-derived treatment designed to stimulate bone formation through gradual release of parathyroid hormone, offering a novel approach to addressing spinal issues and potential opening up a lucrative new market. He goes on to give a summary of the company's half-year results highlighting strong revenue growth in the US and reveals an ambitious five-year growth target. Contact Details Proactive UK Ltd Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

August 11, 2023 11:34 AM Eastern Daylight Time

Video
Article thumbnail News Release

NuggMD Celebrates Launching Services in 23rd State, Washington

NuggMD

NuggMD, the nation's leading medical marijuana telemedicine platform, has launched its service in Washington state for just $139. Since its founding in 2015, NuggMD has connected over 1,000,000 patients to their medical marijuana physicians via its state-of-the-art telehealth platform. "Telehealth has never been more important for patients who are increasingly feeling the pinch of inflation, especially on the West Coast," said Alex Milligan, NuggMD co-founder and CMO. "We're excited to offer our platform to physicians who wish to provide follow-up care to their patients in Washington state, where appropriate." Washington's registered patient population has fallen to nearly half of its peak of over 20,000 registered patients in 2017, with only 6,315 cards issued so far in 2023. Registration with the state is voluntary, but only registered patients are exempt from cannabis retail taxes. "Sure, there are fewer patients now," said Collin Mann, CEO and NuggMD co-founder. "But Washington's medical program is still very important for both registered and unregistered patients. We hope we can help keep that program alive by helping patients more easily access their physicians." NuggMD's platform is available from 8 am to 10 pm seven days a week. No appointment is needed, and patients who don't qualify for their state's medical cannabis program won't be charged for their evaluation. About NuggMD NuggMD is the nation's largest medical marijuana technology platform, serving patients in California, Connecticut, Georgia, Illinois, Iowa, Louisiana, Maine, Maryland, Massachusetts, Michigan, Missouri, Montana, Nevada, New Jersey, New York, Ohio, Oklahoma, Pennsylvania, Texas, Vermont, Virginia, and West Virginia. They've connected over 1,000,000 patients face-to-face with their new medical marijuana doctors via their state-of-the-art telemedicine platform. They believe every human being has the right to explore the benefits of medical cannabis and are fully committed to helping each patient explore every option in their journey to wellness. For further information, visit NuggMD.com/Washington. Contact Details Andrew Graham +1 646-385-0189 andrew.g@getnugg.com Company Website http://www.nuggmd.com

August 10, 2023 05:31 PM Eastern Daylight Time

Article thumbnail News Release

Context Therapeutics CEO Marty Lehr notes progress towards the clinic with CTIM-76 in 2Q update

Context Therapeutics

Context Therapeutics (NASDAQ:CNTX) CEO Marty Lehr takes Proactive's Stephen Gunnion through progress with the company's lead program, CTIM-76. Lehr explained that CTIM-76 is a T cell engaging bispecific antibody targeting Claudin 6 (CLDN6) on tumor cells and CD3 on immune cells. The program is on track for an Investigational New Drug Application (IND) filing in the first quarter of 2024, Lehr added. The company has provided consistent cash guidance to late 2024, which it believes provides adequate capitalization through its next major inflection point. An upcoming preclinical update is anticipated in the second half of 2023 with further information on CTIM-76, relating to its preclinical development, specifically its in vivo efficacy, safety, and tolerability. Lehr also shared Context Therapeutics' focus on manufacturing and safety studies as they move towards the IND filing. He noted that other competitors, including private company TORL Biotherapeutics and BioNTech, which is publicly traded, are planning updates on Claudin 6 before the end of 2023. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

August 10, 2023 02:19 PM Eastern Daylight Time

Video
Article thumbnail News Release

Xeris Biopharma CEO unveils record quarterly revenue, underpinned by unique business model

Xeris Biopharma Holdings

Xeris Biopharma chairman and CEO Paul Edick joined Proactive's Stephen Gunnion with details of the company's second-quarter performance, which saw record revenue driven by the success of their products, including Gvoke, Keveyis, and Recorlev. For the quarter, which ended on June 30, 2023, the company achieved sales of $38 million, up 50% year-over-year and 14% sequentially. Edick noted that Xeris' unique business model includes three pillars: a thriving commercial business, technology for in-house product development, and partnerships to enhance others' drugs. This diversified approach provides the company with strategic flexibility and options for growth. He also expressed confidence in achieving cash flow breakeven by the fourth quarter and emphasized the company's sustainability without the need for additional public equity sales. Regarding the pipeline program for Xerisol levothyroxine, Edick said Xeris is enrolling in the phase two study. The data collected will shape the phase three trial and regulatory negotiations with the US Food and Drug Administration (FDA). Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

August 10, 2023 11:59 AM Eastern Daylight Time

Video
Article thumbnail News Release

Premium Amanita Muscaria Mushroom Gummies Launched by Exhale Wellness

Blue Ribbon Media

Exhale Wellness, a premiere-rated, all-natural hemp brand, becomes the newest addition to the thriving US psychedelics market with its proud range of mystical mushroom gummies. These spellbinding Amanita Muscaria Mushroom Gummies redefine the landscape for psychoactive gummies with 500mg of pure potency, creating a new benchmark for individuals seeking an escape to their happy place. Crafted using pure Amanita mushrooms without any additives or artificial flavoring, these gummies embody a potent, mystical experience with cruelty-free lab certification testifying to its safety. If you're a gummy connoisseur looking to try trend-breaking new launches, this is your sign to get to know Amanita Muscaria Mushroom gummies well. Understanding The Mystical Amanita Gummies & Its Effects Amanita Muscaria Mushrooms are the easiest to recognize. If you've ever encountered soft, white mushrooms with red polka-dotted tops, know these mushrooms can take you on a mind-expanding, marvelous journey. This mushroom's blend of psychoactive alkaloids is particularly responsible for the mystical experience. Among these, the two alkaloid blends that stand out for their prominent psychoactive personalities are muscarine & ibotenic acid. What makes these psychoactive mushrooms different than other psychedelics is their interaction with various receptors, encouraging mild hallucinogenic properties when taken in a high quantity. Unlocking the wonders with Exhale Wellness Amanita Mushroom Gummies If you're looking for a calming, elevating escape in the form of a wholesome treat, the Amanita mushroom gummies could be your go-to munchie destination. These gummies are crafted using all-natural ingredients along with 5mg of Muscimol and 500mg of Amanita muscaria mushroom fruiting body extract. Amanita mushrooms are less powerful than psilocybin, better known as 'magic' mushrooms, and won't cause a steep feeling of intoxication if used responsibly. However, the effects majorly depend on the quantity and compatibility of the user. For new users, 1/2 a gummy would be the best way to start their mushroom gummy journey. If the craving for a better, more elevated experience persists, users can use the other half of the gummy after 2-3 hours to continue their mystical adventure. Where Do Amanita Mushroom Gummies Stand Legally? Amanita Muscaria Mushroom gummies lack the crude potency 'magic' mushrooms or psilocybin contains, and hence, do not fall under the Controlled Substances list. In the US, Louisiana is currently the only state that has imposed limitations on the distribution and sales of Amanita extract and related products. Safety and Thrills Rolled Into One With Exhale Wellness Amanita Mushroom Gummies The market for psychoactive on-the-go treats is ballooning with each passing day, and mushroom gummies are at the top of the trend list, which means newer variations and more refined experiences are on the horizon. New launches like Exhale Wellness' Amanita Muscaria Mushroom gummies are further propelling the expansion and popularity of these fun-sized treats. However, stringent protocols for quality and safety testing are one of the driving factors that distinguish prominent brands like these from others. About Exhale Wellness Exhale Wellness is an all-natural hemp brand highly regarded for its premium-quality hemp. Sustainably sourced from the finest farms in Colorado, Exhale Wellness is known for its extensive line of Delta-8, Delta-9, Delta-10, THC, HHC, and CBD products, with their newest introduction being Amanita Muscaria Mushroom gummies. All products sourced, manufactured, and advertised are USA-made and safety certified through stringent third-party lab tests to ensure the purity and potency of all products. Contact Details Exhale Wellness Support at Exhale Wellness +1 323-448-3810 support@exhalewell.com Company Website https://www.exhalewell.com/

August 10, 2023 07:14 AM Eastern Daylight Time

Article thumbnail News Release

Delivra Health Brands expands Dream Water to Las Vegas resorts

Delivra Health Brands Inc.

Delivra Health Brands Inc president and CEO Gord Davey joins Proactive's Stephen Gunnion with details of a customer merchandising agreement its Dream Water subsidiary has entered into with two Las Vegas resorts, Treasure Island and Circus Circus, for its Dream Water products. Davey emphasized that the collaboration allows Delivra to place its Dream Water products in kiosks across both resorts, enhancing sales in the US market. It also fits with the company's strategic decision to focus on the travel, hotel/resort and entertainment sectors due to the demand for quality sleep solutions during travel. Apart from product placement, Delivra will implement comprehensive marketing initiatives, leveraging social media and peak periods at the resorts to promote their offerings. Delivra's portfolio includes various Dream Water products, such as sleep shots, immunity, beauty, and sleep gummies, which will be accessible not only in airports across North America but also in Hilton Hotels and now, in Las Vegas. Davey noted that the collaboration with Treasure Island and Circus Circus is anticipated to lead to new customer acquisition. Contact Details Proactive Studio +1 604-688-8158 na-editorial@proactiveinvestors.com

August 09, 2023 02:53 PM Eastern Daylight Time

Video
Article thumbnail News Release

Roquefort Therapeutics making headway with siRNA

Roquefort Therapeutics PLC

Roquefort Therapeutics PLC (LSE:ROQ, OTCQB:ROQAF) chief executive Ajan Reginald speaks to Thomas Warner from Proactive after announcing the successful development of new small interfering RNA (siRNA) sequences. Reginald says that siRNA holds immense potential as a cancer treatment, explaining that SiRNA binds to and blocks specific RNA, stopping the production of cancer-fueling substances and ultimately killing cancer cells. He suggests that the technology has been gaining traction since it received the Nobel Prize in 2006, and that Big Pharma is now actively seeking partnerships in the siRNA field. Reginald goes on to say that for Roquefort Therapeutics, the significance of their recent developments lies in their early innovation and focus on STAT6, a key target in their research. The company acquired R&D company Oncogeni last year before STAT6 gained widespread recognition, giving them what he considers a competitive edge in intellectual property and development. He goes on to give a brief overview of the projects Roquefort is currently focused on, concluding by saying that "we're always trying to find new targets... if we can be first to find a new target, that's when shareholders will see very large deals." Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

August 09, 2023 07:48 AM Eastern Daylight Time

Video
Article thumbnail News Release

Longeveron Announces Key Additions To Its Leadership Team and Board As It Gears Up For Phase 2 Trials For Its Lead Drug Candidate For Several Conditions

LONGEVERON INC.

By David Willey, Benzinga Longeveron, Inc. (NASDAQ: LGVN) is a clinical-stage biopharmaceutical company focused on therapies for age-related and life-threatening diseases. Longeveron’s primary drug is Lomecel-B™, which is being developed as a potential therapy for Alzheimer's disease, Aging-Frailty, and a rare pediatric disease, hypoplastic left heart syndrome (HLHS). After almost a decade of research and development (R&D) and collecting safety and efficacy data, the Company is initiating additional phase 2 trials for Lomecel-B™ as a potential treatment for these indications. To help the Company with its continued growth and development, the Company has brought on additional experienced leaders to its board and leadership team. These leaders bring a wealth of expertise in drug development, regulatory filing and product commercialization. Longeveron believes that its recent appointments should inspire even greater confidence in its investors as the Company advances its trials for Lomecel-B™. CEO And Board Member Appointments In March 2023, Longeveron appointed Wa’el Hashad as its new Chief Executive Officer (CEO). Hashad brings over three decades of experience in global pharmaceutical and biotechnology companies like Amgen (NASDAQ: AMGN) and Eli Lilly and Company (NYSE: LLY), and he has been involved in drug development, mergers and acquisitions and product commercialization. Before joining Longeveron, Hashad spent six years as CEO of Avanir Pharmaceuticals, where he oversaw the company’s integration with Otsuka. “I am honored to join Longeveron as CEO,” said Hashad. “With its robust clinical pipeline, Longeveron is well-positioned as a leader in regenerative medicines. I look forward to working with the Board, management, and the broader Longeveron team to continue the impressive progress to date and advance Lomecel-B™ as a potential therapy across multiple disease areas.” Hashad was recently appointed to Longeveron’s Board of Directors, along with prominent biotechnology and corporate management experts Khoso Baluch and Jeffrey Pfeffer. Baluch has 36 years of experience in the biopharmaceutical industry and has held positions at multiple companies including Eli Lilly and CorMedix Inc. and is currently chairman of the board for Poxel SA. Pfeffer also brings extensive management experience to Longeveron as a current and previous board member of more than 10 companies. He is also a respected organizational expert, authoring or co-authoring more than 16 books and serving as a professor at Stanford University Graduate School of Business since the late 1970s. Other Team Appointments The Company also announced two other major additions to its leadership team in the past month. On July 11, 2023, Longeveron appointed Nataliya Agafonova, M.D., as the Company’s Chief Medical Officer (CMO). Agafonova has spent time at a range of high-profile companies and her cross-therapeutic expertise has contributed to multiple drugs being brought to market. She is heading up Longeveron’s global clinical development and spearheading its regulatory strategy for its investigational products. Most recently, the company appointed Lisa Locklear as Longeveron’s Executive Vice President and Chief Financial Officer, effective as of July 31, 2023. Locklear has held a broad array of senior financial roles across the healthcare and other industry sectors and currently serves as a board member for several institutions and is a part of the National Association of Corporate Directors (NACD). The Company believes these appointments put Longeveron in an even stronger position as it focuses on advancing its pipeline for Lomecel-B™. Lomecel-B™ is developed from the bone marrow of young and healthy adult donors into an allogeneic medicinal signaling cell (MSC) therapy product to address multiple diseases. Follow the latest developments from Longeveron by visiting its website. We are a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions.Our lead investigational product is Lomecel-B™, which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young healthy adult donors. We believe that by using the same cells that promote tissue repair, organ maintenance, and immune system function, we can develop safe and effective therapies for some of the most difficult diseases and conditions associated with aging. Forward-Looking StatementsCertain statements in this press release that are not historical facts are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which reflect management's current expectations, assumptions, and estimates of future operations, performance and economic conditions, and involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the statements made herein. Forward-looking statements are generally identifiable by the use of forward-looking terminology such as "believe," "expects," "may," "looks to," "will," "should," "plan," "intend," "on condition," "target," "see," "potential," "estimates," "preliminary," or "anticipates" or the negative thereof or comparable terminology, or by discussion of strategy or goals or other future events, circumstances, or effects. Factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statements in this release include, but are not limited to, statements regarding the offer and sale of securities, the terms of the offering, about the ability of Longeveron’s clinical trials to demonstrate safety and efficacy of the Company’s product candidates, and other positive results; the timing and focus of the Company’s ongoing and future preclinical studies and clinical trials and the reporting of data from those studies and trials; the size of the market opportunity for the Company’s product candidates, including its estimates of the number of patients who suffer from the diseases being targeted; the success of competing therapies that are or may become available; the beneficial characteristics, safety, efficacy and therapeutic effects of the Company’s product candidates; the Company’s ability to obtain and maintain regulatory approval of its product candidates in the U.S., Japan and other jurisdictions; the Company’s plans relating to the further development of its product candidates, including additional disease states or indications it may pursue; the Company’s plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available and its ability to avoid infringing the intellectual property rights of others; the need to hire additional personnel and the Company’s ability to attract and retain such personnel; the Company’s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company’s need to raise additional capital, and the difficulties it may face in obtaining access to capital, and the dilutive impact it may have on its investors; the Company’s financial performance, and the period over which it estimates its existing cash and cash equivalents will be sufficient to fund its future operating expenses and capital expenditure requirements. Additionally, Longeveron makes no assurance that any public offering of its securities as described herein will occur at all, or that any such transaction will occur on the timelines, in the manner or on the terms anticipated due to numerous factors. Further information relating to factors that may impact the Company's results and forward-looking statements are disclosed in the Company's filings with the Securities and Exchange Commission, including Longeveron’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 14, 2023. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company disclaims any intention or obligation, other than imposed by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Christine Petraglia - TraDigital IR +1 844-470-2550 christine@tradigitalir.com Company Website https://longeveron.com/

August 08, 2023 09:25 AM Eastern Daylight Time

1 ... 5859606162 ... 210